Manabu Kawada
Overview
Explore the profile of Manabu Kawada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
1052
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakamoto S, Inoue H, Takino T, Kohda Y, Yoshida J, Ohba S, et al.
Cancer Sci
. 2025 Mar;
PMID: 40079504
Small-cell lung cancer (SCLC) is an aggressive tumor characterized by the frequent development of distant metastases. This study aimed to explore the mechanism of SCLC metastasis using an originally developed...
2.
Shinzawa Y, Sasaki S, Iwabuchi S, Hashimoto S, Kawada M, Hayakawa Y
Biochem Biophys Res Commun
. 2024 Nov;
741:151020.
PMID: 39577078
Although natural killer (NK) cell responses to tumor and viral infection have been studied, the mechanisms underlying NK cell homeostasis in vivo remain unclear. In this study, we demonstrate the...
3.
Shinzawa Y, Hara D, Shinguryo Y, Yokoyama S, Kawada M, Hayakawa Y
Int Immunol
. 2024 Oct;
37(2):97-107.
PMID: 39404747
The transcription factor T-bet is essential for the anti-tumor effector function of natural killer (NK) cells, but the mechanism regulating its expression in NK cells remains unclear. In this study,...
4.
Atsumi S, Nosaka C, Onodera T, Adachi H, Watanabe T, Kawada M, et al.
Biomolecules
. 2024 Sep;
14(9).
PMID: 39334963
We have previously identified Ertredin (3-(2-amino-5-bromophenyl) quinoxalin-2(1H)-one) as a compound that suppresses 3D spheroid formation and tumorigenesis in NIH3T3 cells induced by variant III () transduction. One of its targets...
5.
Ishikawa K, Suzuki H, Ohishi T, Li G, Tanaka T, Kawada M, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273139
CD44 regulates cell adhesion, proliferation, survival, and stemness and has been considered a tumor therapy target. CD44 possesses the shortest CD44 standard (CD44s) and a variety of CD44 variant (CD44v)...
6.
Ishikawa K, Suzuki H, Ohishi T, Nakamura T, Yanaka M, Li G, et al.
Oncol Rep
. 2024 Sep;
52(5).
PMID: 39219278
CD44 is a type I transmembrane glycoprotein associated with poor prognosis in various solid tumors. Since CD44 plays a critical role in tumor development by regulating cell adhesion, survival, proliferation...
7.
Park S, Cho S, Atsumi S, Kawada M, Shibuya M, Lee J, et al.
J Proteome Res
. 2023 Dec;
23(1):130-141.
PMID: 38104258
Many attempts have been made to develop new agents that target EGFR mutants or regulate downstream factors in various cancers. Cell-based screening showed that a natural small molecule, Ertredin, inhibited...
8.
Tatsuda D, Amemiya M, Nosaka C, Sawa R, Muramatsu H, Igarashi M, et al.
J Antibiot (Tokyo)
. 2023 Nov;
77(2):73-84.
PMID: 38001285
Cancer remains one of the leading causes of death worldwide, particularly pancreatic cancer being lethal because of its aggressiveness and lack of early detection methods. A factor that contributes to...
9.
Suzuki H, Ohishi T, Nanamiya R, Kawada M, Kaneko M, Kato Y
Curr Issues Mol Biol
. 2023 Oct;
45(10):7734-7748.
PMID: 37886932
The clinically approved human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibodies (mAbs), trastuzumab, and pertuzumab, target domains IV and II, respectively. Trastuzumab is now the standard treatment for HER2-overexpressed...
10.
Yamazaki Y, Kawada M, Momose I
Oncol Res
. 2023 Sep;
31(6):845-853.
PMID: 37744273
The androgen receptor (AR) is a critical target in all the clinical stages of prostate cancer. To identify a new AR inhibitor, we constructed a new screening system using the...